Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Effects of political conflict-induced treatment interruptions on HIV drug resistance.

Mann M, Lurie MN, Kimaiyo S, Kantor R.

AIDS Rev. 2013 Jan-Mar;15(1):15-24. Review.

2.

Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda.

Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C, Mugyenyi P, Quinn TC, Bangsberg DR.

AIDS. 2007 May 11;21(8):965-71.

PMID:
17457090
3.

Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.

Sanchez R, Portilla J, Gimeno A, Boix V, Llopis C, Sanchez-Paya J, Merino E, de la Sen ML, Muñoz C, Reus S, Plazas J.

J Infect. 2007 Feb;54(2):159-66. Epub 2006 May 11.

PMID:
16690132
4.

Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions.

Schweighardt B, Ortiz GM, Grant RM, Wellons M, Miralles GD, Kostrikis LG, Bartlett JA, Nixon DF.

AIDS. 2002 Nov 22;16(17):2342-4.

PMID:
12441810
5.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
6.

Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.

Nuesch R, Ananworanich J, Sirivichayakul S, Ubolyam S, Siangphoe U, Hill A, Cooper D, Lange J, Phanuphak P, Ruxrungtham K.

Clin Infect Dis. 2005 Mar 1;40(5):728-34. Epub 2005 Feb 4.

7.

Monitoring antiretroviral therapy in resource-limited settings: balancing clinical care, technology, and human resources.

Hosseinipour MC, Schechter M.

Curr HIV/AIDS Rep. 2010 Aug;7(3):168-74. doi: 10.1007/s11904-010-0046-4. Review.

PMID:
20499290
8.

Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults.

Pai NP, Lawrence J, Reingold AL, Tulsky JP.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD006148. Review.

PMID:
16856117
9.

Systematic review of HIV drug resistance in Southeast Asia.

Trotter AB, Hong SY, Srikantiah P, Abeyewickreme I, Bertagnolio S, Jordan MR.

AIDS Rev. 2013 Jul-Sep;15(3):162-70. Review.

10.

Drug resistance mutations during structured interruptions of HAART in two HIV-1-infected children.

Palacios-Saucedo GC, Rivera-Morales LG, Vázquez-Guillén JM, Sánchez LM, Ramírez TJ, Briones E, Ortiz-López R, Vázquez CA, Rodríguez-Padilla C.

Curr HIV Res. 2011 Apr;9(3):154-9.

PMID:
21457133
11.

Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries.

De Luca A, Hamers RL, Schapiro JM.

J Infect Dis. 2013 Jun 15;207 Suppl 2:S63-9. doi: 10.1093/infdis/jit109. Review.

12.

Structured treatment interruptions in antiretroviral management of HIV-1.

Miller V.

Curr Opin Infect Dis. 2001 Feb;14(1):29-37. Review.

PMID:
11979112
13.

Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy.

Imaz A, Olmo M, Peñaranda M, Gutiérrez F, Romeu J, Larrousse M, Domingo P, Oteo JA, Niubó J, Curto J, Vilallonga C, Masiá M, López-Aldeguer J, Iribarren JA, Podzamczer D; STOPAR Study Team.

Antivir Ther. 2012;17(3):577-83. doi: 10.3851/IMP2025. Epub 2011 Dec 19. Erratum in: Antivir Ther. 2012;17(3):597.

PMID:
22301439
14.
15.

Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance.

Grant PM, Zolopa AR.

Curr Opin Investig Drugs. 2010 Aug;11(8):901-10. Review.

PMID:
20721832
16.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV.

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.

PMID:
12617573
17.

No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients.

Ghosn J, Wirden M, Ktorza N, Peytavin G, Aït-Mohand H, Schneider L, Dominguez S, Bricaire F, Calvez V, Costagliola D, Katlama C.

AIDS. 2005 Oct 14;19(15):1643-7.

PMID:
16184034
18.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for the Treatment of HIV.

MMWR Recomm Rep. 2002 May 17;51(RR-7):1-55.

19.

Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.

Taiwo B, Murphy RL, Katlama C.

Drugs. 2010 Sep 10;70(13):1629-42. doi: 10.2165/11538020-000000000-00000. Review.

PMID:
20731472
20.

Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults.

Pai NP, Tulsky JP, Lawrence J, Colford JM Jr, Reingold AL.

Cochrane Database Syst Rev. 2005 Oct 19;(4):CD005482. Review.

PMID:
16235406
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk